Amylyx withdraws ALS drug after trial fail, slashes headcount

The Cambridge biotech has decided to remove its ALS drug from the market after announcing last month it had failed a Phase 3 clinical trial.

Source: bizjournals.com Health Care:Biotechnology headlines - April 4, 2024 Category: Biotechnology Authors: Hannah Green Source Type: news